GlaxoSmithKline plc (GSK)
| Market Cap | 99.28B |
| Revenue (ttm) | 45.37B |
| Net Income (ttm) | 6.05B |
| Shares Out | 2.52B |
| EPS (ttm) | 2.39 |
| PE Ratio | 16.58 |
| Forward PE | 12.41 |
| Dividend | $2.15 (5.44%) |
| Ex-Dividend Date | Aug 19, 2021 |
| Volume | 5,206,519 |
| Open | 39.38 |
| Previous Close | 39.46 |
| Day's Range | 39.28 - 39.56 |
| 52-Week Range | 31.43 - 42.14 |
| Beta | 0.39 |
| Analysts | Buy |
| Price Target | 48.08 (+21.6%) |
| Est. Earnings Date | Oct 27, 2021 |
About GSK
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, ...
Financial Performance
In 2020, GSK's revenue was 34.10 billion, an increase of 1.02% compared to the previous year's 33.75 billion. Earnings were 5.75 billion, an increase of 23.77%.
Financial numbers in millions GBPFinancial StatementsAnalyst Forecast
According to 6 analysts, the average rating for GSK stock is "Buy." The 12-month stock price forecast is 48.08, which is an increase of 21.58% from the latest price.
News
3 Top Stocks You Can Still Buy for Under $20 a Share
These three companies are in the early stages of revolutionizing their specific industries.
Glaxo Should Consider Buying a Headache (Company), Says Industry Consultant
Drug consulting group Evaluate thinks GlaxoSmithKline PLC ( GSK , Financial) should consider making a run at Biohaven Pharmaceutical Holding Company Ltd. ( BHVN , Financial) after the latter recorded ou...
GSK or NVO: Which Is the Better Value Stock Right Now?
GSK vs. NVO: Which Stock Is the Better Value Option?
Is GlaxoSmithKline (GSK) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...
GSK on track with consumer split as buyout report boosts shares
GlaxoSmithKline is "firmly on track" to spin off its consumer health business next year, the British drugmaker said on Tuesday, after Bloomberg News reported the unit could attract bids from private equ...
2 Stocks Set to Win From the Historic Malaria Vaccine Approval
But those wins probably won't be all that big.
GSK to cement split with two new headquarters
GlaxoSmithKline on Monday laid out plans for a new, 120 million pound ($164 million) headquarters for its soon-to-be-independent consumer healthcare business and also said its remaining pharmaceuticals ...
Here's Why 2022 Could Be a Huge Year for GlaxoSmithKline
Another big step in preventing HIV and AIDS has been taken and GlaxoSmithKline is at the forefront.
Glaxo (GSK) Eyes Nod for Triumeq Expanded Use in Pediatric HIV
Glaxo (GSK) seeks approval for a new dispersible single-tablet regimen containing dolutegravir to treat children living with HIV.
Here's a High-Yield Dividend Stock Wall Street Thinks Could Jump 26% Within 12 Months
There's plenty to like with this big pharma stock -- but a few problem spots, too.
GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact
Merck KGaA (OTC: MKGAF) and GlaxoSmithKline Plc (NASDAQ: GSK) have ended their $4 billion collaboration on cancer treatment, bintrafusp alfa. Merck said the move was a mutual decision, primarily due to ...
Merck Announces Mutual Decision to End Bintrafusp Alfa Agreement With GSK
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced a mutual decision with GSK to terminate their agreement on bintrafusp alfa, effective September 30, ...
Glaxo's (GSK) Long-Acting Drug NDA Gets Priority Tag for PrEP
Glaxo's (GSK) HIV subsidiary, ViiV Healthcare gets FDA's priority review for a new drug application for long-acting cabotegravir regimen. ViiV Healthcare signs a deal for developing ultra long-acting HI...
ViiV Healthcare's Dovato Combo Regime Shows Encouraging Long Term Data In HIV Patients
ViiV Healthcare, a joint venture between GlaxoSmithKline plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), and Shionogi, presented three-year results from the TANGO study at IDWeek 2021. Phase 3 TANGO study ass...
GSK, Pfizer Backed Long-Acting HIV Med Under FDA Priority Review As Preventative Option
The FDA has accepted and granted Priority Review to ViiV Healthcare's marketing application seeking approval for injectable cabotegravir long-acting for pre-exposure prophylaxis (PrEP). The priority rev...
Sensodyne® Repair and Protect with Deep Repair is Proud to Deliver a Minty & Whitening Toothpaste, Just in Time for N...
WARREN, N.J., Sept. 28, 2021 /PRNewswire/ -- GSK Consumer Healthcare (LSE/NYSE: GSK) is raising a cup – or two – of coffee to celebrate enjoying life's simple pleasures without the interruption of tooth...
Glaxo - Vir Biotech's COVID Treatment Approved In Japan
Japan's health ministry expert committee has approved GlaxoSmithKline Plc (NYSE: GSK) - Vir Biotechnology Inc's (NASDAQ: VIR) sotrovimab, a COVID-19 antibody therapy. Related Link: GSK - Vir Biotech's...
Activist investor Bluebell takes stake in GSK - FT
Activist investor Bluebell Capital Partners has taken a small stake in British pharmaceuticals group GlaxoSmithKline in efforts to shake up top management, a Financial Times report said on Wednesday.
Glaxo's (GSK) Nucala Gets CHMP Nod for 3 Diseases in Europe
Glaxo (GSK) is seeking approval of Nucala for hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis) and chronic rhinosinusitis with nasal polyps in Europe
5 COVID Vaccine Stocks With Late-Stage Candidates You'll Want to Watch
Their vaccines could be late to the party. But the stocks might still be big winners.
GSK teams with King's College to use AI to fight cancer
Artificial intelligence will be used to develop personalised treatments while investigating role of genetics
Glaxo, Pfizer, J&J and Sanofi Expected to Grab Biggest Shares of RSV Vaccine Business
GlaxoSmithKline PLC ( GSK , Financial) is forecasted to carve out more than 25% of a vaccine market that is expected to reach $10.5 billion by 2030. FiercePharma repotrted three other members of big pha...